Japan Lifeline Co., Ltd. announced today that the following resolution concerning dividends of surplus for the fiscal year ended March 31, 2021 was passed at the board of directors meeting held on May 25, 2021. The resolution will be submitted to the 41st Ordinary General Meeting of Shareholders on June 25, 2021.
1. Details for Dividends
Amount determined
Latest dividend forecast
Results of Previous term
(announced on Jan. 29, 2021)
(FYE March 2020)
Date of record
March 31, 2021
March 31, 2021
March 31, 2020
Cash dividend
49.00 yen
49.00 yen
29.00 yen
(Ordinary dividend: 29.00)
(Ordinary dividend: 29.00)
per share
(Ordinary dividend: 29.00)
(Commemorative dividend: 20.00)
(Commemorative dividend: 20.00)
Total amount
of cash
3,945 million yen
-
2,335 million yen
dividend
Effective date
June 28, 2021
-
June 26, 2020
Dividend
Retained earnings
-
Retained earnings
resource
2. Rationale for the determination of dividends of surplus
Japan Lifeline maintains a stable dividend policy in which it implements measures to return profits to shareholders in a timely manner while it can secure necessary internal reserves. To achieve this goal, the company believes it is necessary to take into account the business results for the fiscal year and demand for funds for future business development. Based on the above policy, Japan Lifeline decided to pay a year-end dividend of 49.00 yen per share (ordinary dividend 29.00 yen and commemorative dividend 20.00 yen).
Attachments
Original document
Permalink
Disclaimer
JLL - Japan Lifeline Co. Ltd. published this content on 25 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2021 07:02:01 UTC.
Japan Lifeline Co., Ltd. is a Japan-based company mainly engaged in the import, manufacture and sale of cardiac circulators and other medical devices. The Company is mainly engaged in the production of rhythm devices, electrophysiological (EP) and ablations, surgical products and intervention products. The rhythm devices include cardiac pacemakers, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and other rhythm devices. The EP and ablations include EP catheters for cardiac arrhythmia examination, ablation catheters for arrhythmia treatment and other EP and ablations. The surgical products include prosthetic heart valves and annuloplasty rings for heart disease surgical treatment, vascular grafts, open stent grafts and stent grafts for aortic disease treatment, as well as other surgical products. The intervention products include balloon catheters, guide wires, penetration catheters and other intervention products.